False resistance after artemether-lumefantrine treatment in a falciparum malaria patient in Turkey: A case report.

Artemisinin-based combination therapy Malaria P. falciparum

Journal

IDCases
ISSN: 2214-2509
Titre abrégé: IDCases
Pays: Netherlands
ID NLM: 101634540

Informations de publication

Date de publication:
2019
Historique:
received: 11 06 2019
revised: 01 07 2019
accepted: 22 07 2019
entrez: 9 11 2019
pubmed: 9 11 2019
medline: 9 11 2019
Statut: epublish

Résumé

Artemisinin-based combination therapy (ACT) is recommended by the World Health Organization as first-line treatment of uncomplicated Plasmodium falciparum malaria. ACT treatments failures among travellers returning from Africa to non-endemic countries are considered to be caused by resistance. We report on a case of artemether-lumefantrine treatment failure in a Turkish traveller with uncomplicated Information on returning travellers, includes ensuring that the patients receive supervised treatment with the recommended dose of a quality controlled medicine, routine follow-up of all cases, assessment of adequate absorption of the drug, and/or testing the prevalence of molecular markers of drug resistance if validated, can be an important source of an early warning system for emerging resistance.

Identifiants

pubmed: 31700799
doi: 10.1016/j.idcr.2019.e00607
pii: S2214-2509(19)30160-X
pii: e00607
pmc: PMC6831798
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e00607

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© 2019 The Authors.

Déclaration de conflit d'intérêts

None of the authors report any conflicts of interest.

Références

Pathog Glob Health. 2013 Jan;107(1):30-4
pubmed: 23432861
Clin Infect Dis. 2017 Jan 15;64(2):199-206
pubmed: 27986683
Trop Med Parasitol. 1993 Jun;44(2):111-2
pubmed: 8367657
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28137810
PLoS One. 2017 Nov 28;12(11):e0188613
pubmed: 29182619
Clin Microbiol Infect. 2003 Jun;9(6):497-504
pubmed: 12848724
J Clin Microbiol. 2006 Mar;44(3):1087-9
pubmed: 16517900

Auteurs

Ozgur Koru (O)

Gulhane Training and Research Hospital, Department of Medical Microbiology, Etlik, Ankara, Turkey.

Ertugrul Yazici (E)

World Health Organization, 20 Avenue Appia, 1211, Geneva 27, Switzerland.

Charlotte Rasmussen (C)

Gulhane Training and Research Hospital, Department of Infectious Diseases, Etlik, Ankara, Turkey.

Pascal Ringwald (P)

Gulhane Training and Research Hospital, Department of Infectious Diseases, Etlik, Ankara, Turkey.

Cumhur Artuk (C)

World Health Organization, 20 Avenue Appia, 1211, Geneva 27, Switzerland.

Orhan Bedir (O)

Gulhane Training and Research Hospital, Department of Medical Microbiology, Etlik, Ankara, Turkey.

Classifications MeSH